HRP20161354T1 - Argininske soli agonista tlr7 - Google Patents

Argininske soli agonista tlr7 Download PDF

Info

Publication number
HRP20161354T1
HRP20161354T1 HRP20161354TT HRP20161354T HRP20161354T1 HR P20161354 T1 HRP20161354 T1 HR P20161354T1 HR P20161354T T HRP20161354T T HR P20161354TT HR P20161354 T HRP20161354 T HR P20161354T HR P20161354 T1 HRP20161354 T1 HR P20161354T1
Authority
HR
Croatia
Prior art keywords
salt
ethoxy
arginine
phosphonoethoxy
naphthyridin
Prior art date
Application number
HRP20161354TT
Other languages
English (en)
Croatian (hr)
Inventor
Stephanie Kay Dodd
Siddartha JAIN
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of HRP20161354T1 publication Critical patent/HRP20161354T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HRP20161354TT 2012-03-07 2013-03-07 Argininske soli agonista tlr7 HRP20161354T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261608011P 2012-03-07 2012-03-07
PCT/EP2013/054548 WO2013131985A1 (en) 2012-03-07 2013-03-07 Immunologically useful arginine salts
EP13708142.8A EP2822947B1 (en) 2012-03-07 2013-03-07 Arginine salts of a tlr7 agonist

Publications (1)

Publication Number Publication Date
HRP20161354T1 true HRP20161354T1 (hr) 2016-12-02

Family

ID=47843276

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20161354TT HRP20161354T1 (hr) 2012-03-07 2013-03-07 Argininske soli agonista tlr7

Country Status (18)

Country Link
US (1) US9320748B2 (enExample)
EP (1) EP2822947B1 (enExample)
JP (1) JP6325986B2 (enExample)
CN (1) CN104203946B (enExample)
AU (1) AU2013229466A1 (enExample)
CA (1) CA2865759C (enExample)
CY (1) CY1118091T1 (enExample)
DK (1) DK2822947T3 (enExample)
ES (1) ES2597755T3 (enExample)
HR (1) HRP20161354T1 (enExample)
HU (1) HUE030175T2 (enExample)
LT (1) LT2822947T (enExample)
MX (1) MX346678B (enExample)
PL (1) PL2822947T3 (enExample)
PT (1) PT2822947T (enExample)
RU (1) RU2014140336A (enExample)
SI (1) SI2822947T1 (enExample)
WO (1) WO2013131985A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010290896B2 (en) 2009-09-02 2014-07-03 Glaxosmithkline Biologicals S.A. Immunogenic compositions including TLR activity modulators
MX343914B (es) 2010-09-01 2016-11-18 Glaxosmithkline Biologicals Sa Adsorcion de inmunopotenciadores en sales metalicas insolubles.
US20140112950A1 (en) 2011-03-02 2014-04-24 Manmohan Singh Combination vaccines with lower doses of antigen and/or adjuvant
JP6345603B2 (ja) 2012-03-08 2018-06-20 ノバルティス アーゲー 追加免疫ワクチンのアジュバント化された処方物
AU2015238512B2 (en) 2014-03-26 2018-02-01 Glaxosmithkline Biologicals S.A. Mutant staphylococcal antigens
EP3061826A1 (en) 2015-02-27 2016-08-31 Novartis AG Flavivirus replicons
WO2021178306A1 (en) * 2020-03-01 2021-09-10 Dynavax Technologies Corporation Coronavirus vaccines comprising a tlr9 agonist
US20220280482A1 (en) * 2021-03-06 2022-09-08 Mind Medicine, Inc. Formulations of psilocin that have enhanced stability
GB202215414D0 (en) 2022-10-18 2022-11-30 Glaxosmithkline Biologicals Sa Vaccine

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6699474B1 (en) 1990-08-20 2004-03-02 Erich Hugo Cerny Vaccine and immunserum against drugs of abuse
EP0967279B1 (en) 1992-03-02 2008-01-02 Novartis Vaccines and Diagnostics S.r.l. Helicobacter pylori cytotoxin useful for vaccines and diagnostics
FR2718452B1 (fr) 1994-04-06 1996-06-28 Pf Medicament Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation.
DE69529219T2 (de) 1994-07-01 2003-11-06 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Helicobacter proteine und impstoffe
GB2324093A (en) 1996-01-04 1998-10-14 Rican Limited Helicobacter pylori bacterioferritin
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
CA2414884A1 (en) 2000-07-03 2002-01-10 Chiron S.P.A. Immunisation against chlamydia pneumoniae
FR2827605B1 (fr) 2001-07-20 2004-07-16 Pf Medicament Nouveaux peptides derives de la proteine g du vrs et leur utilisation dans un vaccin
EP2168596B1 (en) 2001-12-12 2012-05-23 Novartis Vaccines and Diagnostics S.r.l. Immunisation against chlamydia trachomatis
GB0211118D0 (en) 2002-05-15 2002-06-26 Polonelli Luciano Vaccines
CN1809380B (zh) 2002-10-11 2010-05-12 启龙有限公司 广泛防御高毒性脑膜炎球菌谱系的多肽-疫苗
CA2526106A1 (en) 2003-06-26 2005-01-13 Chiron Corporation Immunogenic compositions for chlamydia trachomatis
BRPI0508365A (pt) 2004-03-02 2007-07-24 Chiron Corp composições imunogênicas para chlamydia pneumoniae
SI2351772T1 (sl) 2005-02-18 2016-11-30 Glaxosmithkline Biologicals Sa Proteini in nukleinske kisline iz Escherichia coli povezane z meningitisom/sepso
JP2008530245A (ja) 2005-02-18 2008-08-07 ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド 尿路病原性菌株由来の抗原
US8133973B2 (en) 2005-05-12 2012-03-13 Novartis Vaccines And Diagnostics, S.R.L. Immunogenic compositions for Chlamydia trachomatis
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
US8481057B2 (en) 2005-12-22 2013-07-09 Novartis Vaccines & Diagnostics Srl Chlamydial antigens
EP2586790A3 (en) 2006-08-16 2013-08-14 Novartis AG Immunogens from uropathogenic Escherichia coli
BR122016015627A2 (pt) 2007-10-19 2018-10-30 Novartis Ag kit, composição antigênica liofilizada e método para preparação de uma composição imunogênica
NZ612315A (en) 2009-04-14 2014-10-31 Novartis Ag Compositions for immunising against staphylococcus aureus
US8609106B2 (en) 2009-06-01 2013-12-17 Novartis Ag Combinations of pneumococcal RrgB clades
CA2765112A1 (en) * 2009-06-10 2010-12-16 Novartis Ag Benzonaphthyridine-containing vaccines
JP2013502918A (ja) 2009-08-27 2013-01-31 ノバルティス アーゲー 髄膜炎菌fHBP配列を含むハイブリッドポリペプチド
JO3257B1 (ar) 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
AU2010290896B2 (en) * 2009-09-02 2014-07-03 Glaxosmithkline Biologicals S.A. Immunogenic compositions including TLR activity modulators
MX343914B (es) 2010-09-01 2016-11-18 Glaxosmithkline Biologicals Sa Adsorcion de inmunopotenciadores en sales metalicas insolubles.
WO2012103421A1 (en) 2011-01-27 2012-08-02 Novartis Ag Adjuvant nanoemulsions with crystallisation inhibitors
BR112014004782A2 (pt) * 2011-09-01 2017-03-21 Novartis Ag formulações adjuvantes de antígenos de staphylococcus aureus

Also Published As

Publication number Publication date
MX346678B (es) 2017-03-29
CA2865759C (en) 2020-07-21
SI2822947T1 (sl) 2016-10-28
HUE030175T2 (en) 2017-04-28
RU2014140336A (ru) 2016-04-27
CN104203946B (zh) 2017-03-22
US9320748B2 (en) 2016-04-26
ES2597755T3 (es) 2017-01-20
EP2822947A1 (en) 2015-01-14
CA2865759A1 (en) 2013-09-12
CN104203946A (zh) 2014-12-10
US20150125475A1 (en) 2015-05-07
MX2014010423A (es) 2014-09-22
DK2822947T3 (en) 2016-09-19
PT2822947T (pt) 2016-09-26
EP2822947B1 (en) 2016-08-03
JP6325986B2 (ja) 2018-05-16
CY1118091T1 (el) 2017-06-28
LT2822947T (lt) 2016-10-10
AU2013229466A1 (en) 2014-09-04
JP2015511957A (ja) 2015-04-23
PL2822947T3 (pl) 2017-01-31
WO2013131985A1 (en) 2013-09-12

Similar Documents

Publication Publication Date Title
HRP20202017T1 (hr) Sintetski međuprodukt koristan u dobivanju triazolopiridina inhibitora c-met
RU2014140336A (ru) Иммунологически полезные соли аргинина
JP2013172734A5 (enExample)
JP2015511957A5 (enExample)
BR112013010167A2 (pt) sais de dimetilamida do ácido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-ilamino)-7h-pirrol[2,3-d]pirimidino-6-carboxílico e processos para sua produção
JP2016534081A5 (ja) ゾレドロン酸の増強された経口バイオアベイラビリティーを有する経口剤形を調製する方法
WO2014207708A3 (en) Amino acid and peptide conjugates and conjugation process
JP2014517907A5 (enExample)
RU2013139873A (ru) Опорные отметки для идентификации точки начала в системах определения оптической формы
JP2014525429A5 (enExample)
EP2563790A4 (en) PROCESS FOR A QUATERNARY AMMONIA SALT
EP2822972A4 (en) IMPROVED METHOD FOR THE PRODUCTION OF A PHYSIOLOGICALLY ACTIVE POLYPEPTIDE COMPLEX
WO2015011119A3 (en) Salts of dasatinib in amorphous form
FR2978763B1 (fr) Procede de preparation d'amino-acides ou esters comprenant une etape de metathese
WO2013128419A3 (en) Pharmaceutical compositions comprising boronic acid compounds
FR2994178B1 (fr) Procede de preparation d'un acide carboxylique ou d'un aldehyde
FR2999086B1 (fr) Composition orale et/ou buccale sous forme de film fin d'un principe actif faiblement soluble, son procede de preparation et son utilisation
FR3053336B1 (fr) Procede de preparation de l'acide 2,5-furane dicarboxylique (fdca) a partir de derives de pentoses
EP2711373A4 (en) AMORPHIC ASIAN TROMETHAMINE SALT AND MANUFACTURING METHOD THEREFOR
WO2012112841A3 (en) [1,2,4]oxadiazol-3-yl acid salts and crystalline forms and their preparation
FR2977964B1 (fr) Procede d'acquisition d'un angle de rotation et des coordonnees d'un centre de rotation
FR2990850B1 (fr) Composition cosmetique comprenant l'association d'un derive lipophile de l'acide salicylique, d'un sel ou complexe d'aluminium anti-transpirant et d'un sel d'acide amine n,n-diacide acetique
HK1212154A1 (en) Compositions and methods for improving the compatibility of water soluble herbicide salts
PL2780323T3 (pl) Sposób otrzymywania kwasu chinolinokarboksylowego
FR2992641B1 (fr) Procede de preparation d'un sel de medicament anti-inflammatoire non steroidien